Novel Dual Incretin Receptor Agonists in the Spectrum of Metabolic Diseases with a Focus on Tirzepatide: Real Game-Changers or Great Expectations? A Narrative Review

The prevalence of metabolic diseases including type 2 diabetes (T2D), obesity and non-alcoholic fatty liver disease (NAFLD) increases globally. This highlights an unmet need for identifying optimal therapies for the management of these conditions. Tirzepatide is a novel dual incretin receptor agonis...

Descripción completa

Detalles Bibliográficos
Autores principales: Liarakos, Alexandros Leonidas, Koliaki, Chrysi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10377278/
https://www.ncbi.nlm.nih.gov/pubmed/37509514
http://dx.doi.org/10.3390/biomedicines11071875

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10377278/
https://www.ncbi.nlm.nih.gov/pubmed/37509514
http://dx.doi.org/10.3390/biomedicines11071875

Ejemplares similares